Hiv Antiretroviral Efficacy
Hiv Antiretroviral Efficacy - Related Videos
04:19
Oral Combinational Antiretroviral Therapy to Treat HIV-1 Infection in a Humanized Mouse Model
0 Views •
2025
This video demonstrates an assay to evaluate the effectiveness of oral combined antiretroviral therapy (oral cART) in a human immunodeficiency virus-1 (HIV-1)-infected humanized mouse model. A combination of drugs targeting HIV-1, including nucleoside reverse transcriptase inhibitors and integrase strand transfer inhibitors, is administered along with a nutritional supplement and antibiotics. Following the consumption of this mixture by the humanized mice infected with HIV-1, the effective...
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
0 Views •
Cited by 15 •
2014
Here we describe cellular cytotoxicity and single round infectivity assays that allow for the rapid and accurate screening of compounds to determine their cellular cytotoxicity (CC50) and IC50 values against WT and drug resistant HIV-1.
18:46
Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
0 Views •
Cited by 20 •
2010
Nanoparticles of indinavir, ritonavir, efavirenz and atazanavir were manufactured using wet milling, homogenization and ultrasonication. These nanoformulations, collectively termed nanoformulated antiretroviral therapy (nanoART), assessed macrophage-based drug delivery. Monocyte-derived macrophage nanoART uptake, retention and sustained release were determined. These preliminary studies suggest the potential of nanoART for clinical use.
12:03
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
0 Views •
Cited by 4 •
2016
Methods to evaluate the efficacy and toxicity of RNA molecules targeting post-integration steps of the HIV-1 replication cycle are described. These methods are useful for screening new molecules and optimizing the format of existing ones.
06:07
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
0 Views •
Cited by 3 •
2022
This protocol describes a novel method to deliver oral combinational antiretroviral drugs that successfully suppress HIV-1 RNA replication in humanized mice.
FAQs
Combination regimens can target several stages of HIV replication, including reverse transcription, integration, protease-mediated maturation, and viral entry. By placing pharmacologic barriers at distinct points in the viral life cycle, they provide a coordinated strategy for suppressing replication rather than relying on one stage alone. This multi-stage design is central to evaluating durable treatment performance.
Viral load and immune function capture complementary outcomes. Viral-load reduction indicates that replication is being suppressed, while preservation of immune function reflects whether treatment is supporting the host’s broader biological status. Considering both prevents efficacy evaluation from relying on a single indicator and helps connect treatment performance with the goal of limiting viral persistence.
Resistance management is integrated into efficacy planning rather than treated as a separate concern. The overview connects combination regimens, multiple viral-life-cycle targets, and resistance management, indicating that regimen evaluation should consider how suppression is supported across reverse transcription, integration, protease-mediated maturation, and entry over time.
A bioengineering-oriented evaluation can combine laboratory models, computational approaches, and efficacy measurements. These tools support development and evaluation, while viral-load reduction and preservation of immune function provide outcome measures. Together, they connect engineered treatment strategies with observable evidence of suppression and treatment performance.
Targeted drug-delivery systems focus engineering attention on medication distribution. In the stated bioengineering context, improving distribution complements efforts to enhance adherence and manage resistance, rather than replacing the pharmacologic actions of antiretroviral classes. This makes delivery design relevant to treatment strategies seeking more durable outcomes.
Long-acting formulations address a central treatment-design challenge: sustaining medication use over time. The overview identifies adherence as a target for bioengineering improvements, so these formulations are evaluated not only for pharmacologic activity but also for their potential to support durable treatment outcomes. Their value connects formulation design with treatment continuity.
HIV antiretroviral efficacy research provides a framework for linking biological suppression with engineered treatment solutions. Findings about viral-load reduction, immune-function preservation, medication distribution, adherence, and resistance management can guide targeted delivery systems, long-acting formulations, laboratory models, and computational approaches. Together, these directions inform therapies designed for more durable outcomes.